Akari Therapeutics, Plc (AKTX)Healthcare | Biotechnology | Tampa, United States | NasdaqCM
7.40 USD
-0.50
(-6.329%) ⇩
(Oct. 14, 2026, 1:19 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:08 a.m. EDT
The long-term outlook is catastrophic for a traditional value investor. The business has endured a brutal nine-year decline, losing 99.45% of its value, with five consecutive years of negative annual returns ending in a sharp drop. This is not a temporary setback; it is a structural implosion where the market has repeatedly rejected the company's thesis. Fundamentals confirm the distress: negative equity, massive losses, and a balance sheet that barely covers operations without constant capital raises. While the recent 50% surge on KRAS data offers a glimmer of hope for a turnaround, the price-to-book ratio of under 1.0 reflects a deep skepticism that the current assets can generate value. For the short term, the sentiment remains fragile; the options market is screaming 'downside protection,' with put volume dwarfing call activity and implied volatility skewed heavily toward a fall. The statistical forecast model is useless here due to extremely low reliability, so we must rely on the hard reality of the balance sheet and the relentless multi-year price destruction. This is a speculative gamble on a clinical trial success, not an investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.153577 |
| AutoETS | 0.163896 |
| AutoTheta | 0.168010 |
| AutoARIMA | 0.286338 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 10.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.110 |
| Excess Kurtosis | -1.50 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.727 |
| Market Cap | 16,910,222 |
| Forward P/E | -0.86 |
| Beta | 1.44 |
| Website | https://www.akaritx.com |
As of Oct. 10, 2026, 1:08 a.m. EDT: Speculators are positioning defensively with heavy open interest in out-of-the-money puts ($5 strike) relative to calls, while call volume is negligible. Implied volatility is significantly elevated for puts (542%) compared to calls (50%), indicating a market expectation of further downside or a 'long gamma' squeeze scenario where sellers are hedging against a drop. The lack of call volume suggests no active bullish speculation despite the recent 50% pop.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.75914633 |
| Address1 | 401 East Jackson Street |
| Address2 | Suite 3300 |
| All Time High | 95,200.0 |
| All Time Low | 3.015 |
| Ask | 8.21 |
| Ask Size | 19 |
| Average Daily Volume10 Day | 42,190 |
| Average Daily Volume3 Month | 61,306 |
| Average Volume | 61,306 |
| Average Volume10Days | 42,190 |
| Beta | 1.44 |
| Bid | 7.2 |
| Bid Size | 2 |
| Book Value | 10.623 |
| City | Tampa |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.4 |
| Current Ratio | 0.597 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.0999 |
| Day Low | 7.19 |
| Debt To Equity | 3.727 |
| Display Name | Akari Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,892,800 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 8,380,158 |
| Eps Current Year | -9.05 |
| Eps Forward | -8.65 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 929 274 7553 |
| Fifty Day Average | 9.04928 |
| Fifty Day Average Change | -1.6492801 |
| Fifty Day Average Change Percent | -0.18225539 |
| Fifty Two Week Change Percent | -75.914635 |
| Fifty Two Week High | 36.76 |
| Fifty Two Week High Change | -29.359999 |
| Fifty Two Week High Change Percent | -0.79869425 |
| Fifty Two Week Low | 3.015 |
| Fifty Two Week Low Change | 4.385 |
| Fifty Two Week Low Change Percent | 1.4543947 |
| Fifty Two Week Range | 3.015 - 36.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,389,018,600,000 |
| Float Shares | 1,355,937 |
| Forward Eps | -8.65 |
| Forward P E | -0.8554914 |
| Free Cashflow | -9,383,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.5 |
| Fullday Change Percent | -6.329114 |
| Fullday Price | 7.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1325 |
| Held Percent Institutions | 0.10521 |
| Implied Shares Outstanding | 2,285,165 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,915,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida. |
| Long Name | Akari Therapeutics, Plc |
| Market | us_market |
| Market Cap | 16,910,222 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_306632341 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -30,960,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,807,842 |
| Number Of Analyst Opinions | 3 |
| Open | 8.0999 |
| Operating Cashflow | -10,759,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 929 274 7510 |
| Previous Close | 7.9 |
| Price Eps Current Year | -0.8176795 |
| Price Hint | 2 |
| Price To Book | 0.6966017 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.552 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.5 |
| Regular Market Change Percent | -6.329114 |
| Regular Market Day High | 8.0999 |
| Regular Market Day Low | 7.19 |
| Regular Market Day Range | 7.19 - 8.0999 |
| Regular Market Open | 8.0999 |
| Regular Market Previous Close | 7.9 |
| Regular Market Price | 7.4 |
| Regular Market Time | 1,791,998,373 |
| Regular Market Volume | 27,539 |
| Return On Assets | -0.191 |
| Return On Equity | -1.4009 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,285,165 |
| Shares Percent Shares Out | 0.0064 |
| Shares Short | 14,529 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 30,117 |
| Short Name | Akari Therapeutics Plc |
| Short Percent Of Float | 0.01 |
| Short Ratio | 0.18 |
| Source Interval | 15 |
| State | FL |
| Symbol | AKTX |
| Target High Price | 30.0 |
| Target Low Price | 19.5 |
| Target Mean Price | 25.5 |
| Target Median Price | 27.0 |
| Total Cash | 7,694,000 |
| Total Cash Per Share | 3.952 |
| Total Debt | 693,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.23631 |
| Two Hundred Day Average Change | -1.8363099 |
| Two Hundred Day Average Change Percent | -0.19881423 |
| Type Disp | Equity |
| Volume | 27,539 |
| Website | https://www.akaritx.com |
| Zip | 33,602 |